Literature DB >> 26743209

Current understanding of metformin effect on the control of hyperglycemia in diabetes.

Hongying An1, Ling He2.   

Abstract

Metformin is a first-line oral anti-diabetic agent that has been used clinically to treat patients with type 2 diabetes for over 60 years. Due to its efficacy in therapy and affordable price, metformin is taken by more than 150 million people each year. Metformin improves hyperglycemia mainly through the suppression of hepatic gluconeogenesis along with the improvement of insulin signaling. However, its mechanism of action remains partially understood and controversial, especially in regard to the role of AMPK in metformin's action and the mechanism of AMPK activation. In this review, we discuss recent advances in the understanding of metformin's suppression of hepatic glucose production and the mechanism related to the improvement of insulin signaling.
© 2016 Society for Endocrinology.

Entities:  

Keywords:  glucose metabolism; insulin action; liver; metabolism

Mesh:

Substances:

Year:  2016        PMID: 26743209      PMCID: PMC5077246          DOI: 10.1530/JOE-15-0447

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  71 in total

1.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.

Authors:  M R Owen; E Doran; A P Halestrap
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  Potential biomarker of metformin action.

Authors:  Ling He; Shumei Meng; Emily L Germain-Lee; Sally Radovick; Fredric E Wondisford
Journal:  J Endocrinol       Date:  2014-03-17       Impact factor: 4.286

3.  Mechanisms underlying the resistance to diet-induced obesity in germ-free mice.

Authors:  Fredrik Bäckhed; Jill K Manchester; Clay F Semenkovich; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-08       Impact factor: 11.205

4.  Mechanism by which metformin reduces glucose production in type 2 diabetes.

Authors:  R S Hundal; M Krssak; S Dufour; D Laurent; V Lebon; V Chandramouli; S E Inzucchi; W C Schumann; K F Petersen; B R Landau; G I Shulman
Journal:  Diabetes       Date:  2000-12       Impact factor: 9.461

5.  Quantitative contributions of gluconeogenesis to glucose production during fasting in type 2 diabetes mellitus.

Authors:  A Wajngot; V Chandramouli; W C Schumann; K Ekberg; P K Jones; S Efendic; B R Landau
Journal:  Metabolism       Date:  2001-01       Impact factor: 8.694

6.  Inactivation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in vitro. An adenine nucleotide-dependent reaction catalyzed by a factor in human fibroblasts.

Authors:  M S Brown; G Y Brunschede; J L Goldstein
Journal:  J Biol Chem       Date:  1975-04-10       Impact factor: 5.157

7.  Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers.

Authors:  Luying Peng; Zhong-Rong Li; Robert S Green; Ian R Holzman; Jing Lin
Journal:  J Nutr       Date:  2009-07-22       Impact factor: 4.798

8.  Structure of mammalian AMPK and its regulation by ADP.

Authors:  Bing Xiao; Matthew J Sanders; Elizabeth Underwood; Richard Heath; Faith V Mayer; David Carmena; Chun Jing; Philip A Walker; John F Eccleston; Lesley F Haire; Peter Saiu; Steven A Howell; Rein Aasland; Stephen R Martin; David Carling; Steven J Gamblin
Journal:  Nature       Date:  2011-03-13       Impact factor: 49.962

9.  Physical exercise reduces circulating lipopolysaccharide and TLR4 activation and improves insulin signaling in tissues of DIO rats.

Authors:  Alexandre G Oliveira; Bruno M Carvalho; Natália Tobar; Eduardo R Ropelle; José R Pauli; Renata A Bagarolli; Dioze Guadagnini; José B C Carvalheira; Mario J A Saad
Journal:  Diabetes       Date:  2011-01-31       Impact factor: 9.461

10.  AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation.

Authors:  Graeme J Gowans; Simon A Hawley; Fiona A Ross; D Grahame Hardie
Journal:  Cell Metab       Date:  2013-10-01       Impact factor: 27.287

View more
  58 in total

Review 1.  The effects of metformin on gut microbiota and the immune system as research frontiers.

Authors:  Michael Pollak
Journal:  Diabetologia       Date:  2017-08-02       Impact factor: 10.122

Review 2.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

3.  Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota.

Authors:  Aneseh Adeshirlarijaney; Jun Zou; Hao Q Tran; Benoit Chassaing; Andrew T Gewirtz
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-10-01       Impact factor: 4.310

4.  Favorable outcomes of metformin on coronary microvasculature in experimental diabetic cardiomyopathy.

Authors:  Ahmed A M Abdel-Hamid; Alaa El-Din L Firgany
Journal:  J Mol Histol       Date:  2018-10-13       Impact factor: 2.611

5.  Regulation of hepatic gluconeogenesis by nuclear factor Y transcription factor in mice.

Authors:  Yanjie Zhang; Qiuyue Guan; Yin Liu; Yuwei Zhang; Yulong Chen; Jinglu Chen; Yulan Liu; Zhiguang Su
Journal:  J Biol Chem       Date:  2018-03-12       Impact factor: 5.157

Review 6.  Physiological insights into novel therapies for nephrogenic diabetes insipidus.

Authors:  Jeff M Sands; Janet D Klein
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-17

7.  Small molecule IVQ, as a prodrug of gluconeogenesis inhibitor QVO, efficiently ameliorates glucose homeostasis in type 2 diabetic mice.

Authors:  Ting-Ting Zhou; Tong Zhao; Fei Ma; Yi-Nan Zhang; Jing Jiang; Yuan Ruan; Qiu-Ying Yan; Gai-Hong Wang; Jin Ren; Xiao-Wei Guan; Jun Guo; Yong-Hua Zhao; Ji-Ming Ye; Li-Hong Hu; Jing Chen; Xu Shen
Journal:  Acta Pharmacol Sin       Date:  2019-03-04       Impact factor: 6.150

Review 8.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

Review 9.  AMPK: guardian of metabolism and mitochondrial homeostasis.

Authors:  Sébastien Herzig; Reuben J Shaw
Journal:  Nat Rev Mol Cell Biol       Date:  2017-10-04       Impact factor: 94.444

10.  Activation of the cAMP-PKA pathway Antagonizes Metformin Suppression of Hepatic Glucose Production.

Authors:  Ling He; Evan Chang; Jinghua Peng; Hongying An; Sara M McMillin; Sally Radovick; Constantine A Stratakis; Fredric E Wondisford
Journal:  J Biol Chem       Date:  2016-03-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.